91 related articles for article (PubMed ID: 11874929)
1. Basal and postglucagon C-peptide levels in Ethiopians with diabetes.
Siraj ES; Reddy SS; Scherbaum WA; Abdulkadir J; Hammel JP; Faiman C
Diabetes Care; 2002 Mar; 25(3):453-7. PubMed ID: 11874929
[TBL] [Abstract][Full Text] [Related]
2. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.
Gjessing HJ; Matzen LE; Faber OK; Frøland A
Diabetologia; 1989 May; 32(5):305-11. PubMed ID: 2666217
[TBL] [Abstract][Full Text] [Related]
3. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients.
Covic AM; Schelling JR; Constantiner M; Iyengar SK; Sedor JR
Kidney Int; 2000 Oct; 58(4):1742-50. PubMed ID: 11012908
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
5. The clinical and hormonal (C-peptide and glucagon) profile and liability to ketoacidosis during nutritional rehabilitation in Ethiopian patients with malnutrition-related diabetes mellitus.
Abdulkadir J; Mengesha B; Welde Gebriel Z; Keen H; Worku Y; Gebre P; Bekele A; Urga K; Taddesse AS
Diabetologia; 1990 Apr; 33(4):222-7. PubMed ID: 2112100
[TBL] [Abstract][Full Text] [Related]
6. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
7. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
Montgomery TM; Nelson RW; Feldman EC; Robertson K; Polonsky KS
J Vet Intern Med; 1996; 10(3):116-22. PubMed ID: 8743209
[TBL] [Abstract][Full Text] [Related]
8. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of the glucagon test in the study of pancreatic islet cell function].
Llorente I; Goñi MJ; Forga L; Monreal M; Lizcano F; Moncada E
Rev Med Univ Navarra; 1992; 37(1):25-9. PubMed ID: 1626165
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
Viikari J; Rönnemaa T; Koskinen P
Ann Clin Res; 1987; 19(3):178-82. PubMed ID: 3314647
[TBL] [Abstract][Full Text] [Related]
11. Islet cell-associated autoantibodies in Ethiopians with diabetes mellitus.
Siraj ES; Gupta MK; Yifter H; Ahmed A; Kebede T; Reja A; Abdulkadir J
J Diabetes Complications; 2016 Aug; 30(6):1039-42. PubMed ID: 27220543
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients.
Laakso M; Rönnemaa T; Sarlund H; Pyörälä K; Kallio V
Diabetes Care; 1989 Feb; 12(2):83-8. PubMed ID: 2649329
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of insulin deficiency among initially non-insulin-dependent middle-aged diabetic individuals.
Laakso M; Sarlund H; Pyörälä K
Diabetes Care; 1986; 9(3):228-31. PubMed ID: 3525053
[TBL] [Abstract][Full Text] [Related]
14. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
[TBL] [Abstract][Full Text] [Related]
15. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level.
De La Tour DD; Raccah D; Jannot MF; Coste T; Rougerie C; Vague P
Diabetologia; 1998 Sep; 41(9):1080-4. PubMed ID: 9754827
[TBL] [Abstract][Full Text] [Related]
16. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics.
Kyllästinen M; Elfving S
Gerontology; 1986; 32(6):317-26. PubMed ID: 3556328
[TBL] [Abstract][Full Text] [Related]
17. Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide. Effect on glycaemic control, serum lipids and lipoproteins.
Laakso M; Sarlund H; Korhonen T; Voutilainen E; Majander H; Hakala P; Uusitupa M; Pyörälä K
Acta Med Scand; 1988; 223(1):61-8. PubMed ID: 3279723
[TBL] [Abstract][Full Text] [Related]
18. [C-peptide assays of the urine and plasma at baseline and under stimulation with glucagon in healthy subjects and diabetics].
Sabot O; Tourniaire J; Charrie A; Rebattu B; Jouve M; Ayzac L; Fleury MC
Presse Med; 1990 May; 19(18):860-3. PubMed ID: 2140181
[TBL] [Abstract][Full Text] [Related]
19. [C-peptide measurement in the classification of diabetes mellitus and in the assessment of requirements for insulin treatment].
Gjessing HJ
Ugeskr Laeger; 1990 Feb; 152(9):588-93. PubMed ID: 2408222
[TBL] [Abstract][Full Text] [Related]
20. Metabolic abnormalities in offspring of NIDDM patients with a family history of diabetes mellitus.
Migdalis IN; Zachariadis D; Kalogeropoulou K; Nounopoulos C; Bouloukos A; Samartzis M
Diabet Med; 1996 May; 13(5):434-40. PubMed ID: 8737025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
